CN113286584A - 治疗骨髓增生性病症的方法 - Google Patents

治疗骨髓增生性病症的方法 Download PDF

Info

Publication number
CN113286584A
CN113286584A CN201980070403.4A CN201980070403A CN113286584A CN 113286584 A CN113286584 A CN 113286584A CN 201980070403 A CN201980070403 A CN 201980070403A CN 113286584 A CN113286584 A CN 113286584A
Authority
CN
China
Prior art keywords
thiamine
patient
compound
myelofibrosis
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980070403.4A
Other languages
English (en)
Chinese (zh)
Inventor
T·贝里
J·胡德
C·贾米森
C·L·斯克里布纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Impact Biomedicines Inc
Original Assignee
Impact Biomedicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69950867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN113286584(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Impact Biomedicines Inc filed Critical Impact Biomedicines Inc
Publication of CN113286584A publication Critical patent/CN113286584A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CN201980070403.4A 2018-09-25 2019-09-24 治疗骨髓增生性病症的方法 Pending CN113286584A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862736369P 2018-09-25 2018-09-25
US62/736,369 2018-09-25
US201862783076P 2018-12-20 2018-12-20
US62/783,076 2018-12-20
PCT/US2019/052608 WO2020068755A1 (en) 2018-09-25 2019-09-24 Methods of treating myeloproliferative disorders

Publications (1)

Publication Number Publication Date
CN113286584A true CN113286584A (zh) 2021-08-20

Family

ID=69950867

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980070403.4A Pending CN113286584A (zh) 2018-09-25 2019-09-24 治疗骨髓增生性病症的方法

Country Status (14)

Country Link
US (2) US20220031699A1 (https=)
EP (1) EP3856169A4 (https=)
JP (2) JP2022502492A (https=)
KR (2) KR20210102192A (https=)
CN (1) CN113286584A (https=)
AU (1) AU2019346521B2 (https=)
BR (1) BR112021005518A2 (https=)
CL (1) CL2021000744A1 (https=)
IL (1) IL281736A (https=)
MA (1) MA53741A (https=)
MX (2) MX2021003450A (https=)
MY (1) MY209349A (https=)
SG (1) SG11202103019WA (https=)
WO (1) WO2020068755A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3856189A4 (en) * 2018-09-25 2022-06-29 Impact Biomedicines, Inc. Methods of treating myeloproliferative disorders
WO2020068755A1 (en) 2018-09-25 2020-04-02 Impact Biomedicines, Inc. Methods of treating myeloproliferative disorders
EP3923948A4 (en) 2019-02-12 2022-11-16 Impact Biomedicines, Inc. CRYSTALLINE SHAPES OF A JAK2 INHIBITOR
JP2024501640A (ja) * 2020-12-16 2024-01-15 インパクト バイオメディシンズ インコーポレイテッド フェドラチニブの投薬
MX2023009858A (es) 2021-02-25 2023-09-12 Impact Biomedicines Inc Uso de inhibidores de proteina de bromodominio y motivo extraterminal (bet) solo o en combinacion con fedratinib o ruxolitinib como tratamiento para una malignidad hematologica tal como la mielofibrosis.
WO2023044297A1 (en) 2021-09-14 2023-03-23 Impact Biomedicines, Inc. Fedratinib for treating myeloproliferative disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108348578A (zh) * 2015-08-04 2018-07-31 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103626742B (zh) * 2005-11-01 2017-04-26 塔格根公司 激酶的联-芳基间-嘧啶抑制剂
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US20090093009A1 (en) * 2007-10-09 2009-04-09 Sum Chan Mass spectrometry method for measuring thiamine in body fluid
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
US20130102624A1 (en) * 2011-05-19 2013-04-25 John V. Schloss Early detection of thiamine deficiency
US10155987B2 (en) 2012-06-12 2018-12-18 Dana-Farber Cancer Institute, Inc. Methods of predicting resistance to JAK inhibitor therapy
WO2015081127A2 (en) 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
CA2936865A1 (en) * 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
WO2020068755A1 (en) 2018-09-25 2020-04-02 Impact Biomedicines, Inc. Methods of treating myeloproliferative disorders
EP3856189A4 (en) 2018-09-25 2022-06-29 Impact Biomedicines, Inc. Methods of treating myeloproliferative disorders
FR3092581A1 (fr) 2019-02-12 2020-08-14 Impact Biomedicines, Inc Formes cristallines d'un inhibiteur de jak2
EP3923948A4 (en) 2019-02-12 2022-11-16 Impact Biomedicines, Inc. CRYSTALLINE SHAPES OF A JAK2 INHIBITOR

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108348578A (zh) * 2015-08-04 2018-07-31 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CURTO-GARCIA ET AL.: "Thiamine deficiency appears uncommon in patients with Myeloproliferative Neoplasms", BRITISH JOURNAL OF HAEMATOLOGY, 2 May 2016 (2016-05-02), pages 338 - 340 *
PARDANANI ET AL.: "Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis A Randomized Clinical Trial", JAMA ONCOLOGY, 18 June 2015 (2015-06-18), pages 643 - 651 *

Also Published As

Publication number Publication date
AU2019346521B2 (en) 2025-05-08
JP2022502492A (ja) 2022-01-11
WO2020068755A1 (en) 2020-04-02
AU2019346521A1 (en) 2021-05-20
MY209349A (en) 2025-07-03
BR112021005518A2 (pt) 2021-06-29
US11400092B2 (en) 2022-08-02
KR20250164332A (ko) 2025-11-24
US20220133724A1 (en) 2022-05-05
MX2023013844A (es) 2023-12-08
CL2021000744A1 (es) 2021-10-08
US20220031699A1 (en) 2022-02-03
MX2021003450A (es) 2021-07-16
EP3856169A4 (en) 2022-06-29
EP3856169A1 (en) 2021-08-04
KR20210102192A (ko) 2021-08-19
JP2024161416A (ja) 2024-11-19
MA53741A (fr) 2021-08-04
SG11202103019WA (en) 2021-04-29
IL281736A (en) 2021-05-31

Similar Documents

Publication Publication Date Title
US11400092B2 (en) Methods of treating myeloproliferative disorders
Verstovsek Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis
US9364476B2 (en) Methods of treating a Bruton's Tyrosine Kinase disease or disorder
Fenn et al. Phase 1 study of erlotinib and metformin in metastatic triple-negative breast cancer
EA028414B1 (ru) Лечение рака ингибиторами tor киназы
EP2922827A2 (en) Methods of treating a disease or disorder associated with bruton's tyrosine kinase
CN113453671A (zh) 用于治疗癌症的Raf抑制剂和CDK4/6抑制剂的组合疗法
CN113286593A (zh) 治疗骨髓增生性病症的方法
JP2007526882A (ja) リンパ球性白血病を治療するためのロスコビチンの使用
EP2754441B1 (en) Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives
JP2017509671A (ja) カロリー摂取量減少と協同したがん治療方法で使用されるチロシンキナーゼ阻害剤
KR20160090814A (ko) Jak, cdk 및 pim의 억제제를 포함하는 조합 요법
US20140142128A1 (en) Methods of treating a disease or disorder associated with bruton's tyrosine kinase
HK40049559A (en) Methods of treating myeloproliferative disorders
EA051859B1 (ru) Способы лечения миелопролиферативных расстройств
EA048287B1 (ru) Способы лечения миелопролиферативных расстройств
Chandu et al. a review on breast cancer in a young women and oppurnities in treatment
Gutierrez et al. 4CPS-211 Analysis of the prescription of vitamin D supplements in a social health centre
KR20260026127A (ko) 대장암 또는 돌연변이성 대장암 치료를 위한 mek 억제제 및 pkl1 억제제의 병용 요법
WO2023067483A1 (en) Pharmaceutical combinations comprising an mdm2 inhibitor, a bcl2 inhibitor and a hypomethylating agent and uses thereof for the treatment of haematological malignancies
Mydlowska et al. P-270 Updated results of Maria Sklodowska-Curie National Research Institute of Oncology gastric cancer cohort: Indirect comparison between adjuvant chemoradiation and perioperative chemotherapy in gastric cancer patients
AU2012321091B2 (en) Methods of treating a Bruton's Tyrosine Kinase disease or disorder
HK40118757A (zh) 用於治疗癌症的包含gdc-6036和gdc-0077的组合疗法
Dabich et al. Alternated Versus Syncopated CHOP-PVB: Two Studies for the Treatment of Non-Hodgkin's Lymphoma by the Southwest Oncology Group

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40049559

Country of ref document: HK